#Multiple Myeloma #CellsBin #CB-Insight

CellsBin's Groundbreaking Achievement in Oncology

CellsBin®, a trailblazer in Rare-Cell Biology™, has recently announced a significant milestone in cancer diagnostics. The biotechnology company received the Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI) to advance its innovative blood-based diagnostic test for multiple myeloma, a cancer that primarily affects the bone marrow.

Redefining Myeloma Diagnosis

Multiple myeloma is known for its complexity, often requiring invasive procedures like bone marrow biopsies to diagnose. Traditional methods involve extracting samples directly from the bone, which can be uncomfortable for patients. However, CellsBin's approach diverges from this norm by detecting circulating myeloma cells in the bloodstream. By capturing these cells and analyzing them, the goal is to provide oncologists with comparable insights to those obtained through a bone marrow sample, and all from a simple blood draw.

Dr. Natalia Neparidze, an Associate Professor of Medicine at Yale, emphasizes the potential here: "Blood is the next frontier in multiple myeloma. Our vision is to enable physicians to gain biological insights from a regular blood draw, which would allow for more frequent monitoring without the discomfort associated with traditional biopsies."

Innovative Technology Underpinning the Study

The funding from the NCI is poised to bolster CellsBin's development of CB-Insight™, a technology that utilizes advanced methods combining high-resolution imaging, microfluidics, and machine learning. This unique blend allows for the detection and recovery of minute populations of myeloma cells from blood samples. Preserving these cells in their live state means that a much richer, more detailed analysis can be conducted, including genomic and molecular profiling.

The clinical study backed by the NCI will enroll patients to validate how effectively CellsBin's technology detects and extracts living myeloma cells. The study, led by Elan Gorshein, DO, JD, MPH, Assistant Professor at Yale, hopes to establish an effective comparison with existing standard clinical testing like traditional bone marrow analyses.

Dr. Gorshein notes, "The pivotal question we face is whether this technology works reliably across diverse patient scenarios. If we can consistently recover viable myeloma cells from blood samples, it represents a transformative approach to monitor and understand the evolution of this disease over time."

Shifting the Paradigm in Myeloma Monitoring

With CellsBin's innovation, the aim is not merely to identify a rare disease marker but to establish a reliable protocol for retrieving living myeloma cells. This ability could radically transform how healthcare providers track patient conditions, making regular blood assessments a viable alternative to periodic biopsies.

According to Ali Kabiri, PhD, Co-founder and CEO of CellsBin,